EXACT Therapeutics AS, a clinical stage biopharmaceutical company, develops a technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT). The ACT is an approach to ultrasound-mediated, targeted drug enhancement with the potential to amplify the clinical utility of a range of therapeutic agents across various indications, including within oncology and brain diseases. The company’s ACT platform is under Phase I clinical trial for treatment of liver metastases; and pre-clinical studies for pancreatic, glioblastoma, and immunotherapy diseases, as well as CNS diseases and gene therapy. It has a collaboration with GE Healthcare. The company was formerly known as Phoenix Solutions AS. EXACT Therapeutics AS was founded in 2012 and is based in Oslo, Norway.
Metrics to compare | EXTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEXTXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.4x | −1.8x | −0.6x | |
PEG Ratio | −0.11 | 0.01 | 0.00 | |
Price/Book | 1.5x | 3.0x | 2.6x | |
Price / LTM Sales | - | 3.6x | 3.4x | |
Upside (Analyst Target) | - | 68.8% | 39.1% | |
Fair Value Upside | Unlock | 11.3% | 5.4% | Unlock |